drugset / Trial / NCT00980343

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

NCT00980343

Phase 2 Completed 44 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. GDC-0449 may be effective in treating patients with glioblastoma multiforme.

Timeline

Start
2010-02
Primary completion
2012-05
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vismodegib Small molecule Oral